A new dawn for Oxford BioMedica…again
This article was originally published in Scrip
Executive Summary
For Oxford BioMedica 2013 was quite an annus horribilis. However, the UK biotechnology firm is still confident it will rise up from the ashes this year – with CEO John Dawson saying that despite reporting pre-tax losses of more than £12m last year, the company is "operationally now in its strongest position ever."